Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.33 |
| ▸ | CALCA | P06881 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336919 | 0.88 | EGLN1 (0.44) | EGLN1HIF1A | |
| SCHEMBL336906 | 0.82 | EGLN1 (0.41) | EGLN1HIF1A | |
| SCHEMBL337721 | 0.81 | EGLN1 (0.39) | EGLN1HIF1A | |
| SCHEMBL12101568 | 0.72 | HIF1A (0.41) | EGLN1HIF1ARAB9AKMT2AKDM4E | |
| SCHEMBL12101565 | 0.72 | EGLN1 (0.43) | EGLN1HIF1ANPC1 | |
| SCHEMBL12172226 | 0.72 | EGLN1 (0.43) | EGLN1HIF1ARAB9AKMT2AKDM4E | |
| SCHEMBL337692 | 0.71 | HIF1A (0.45) | EGLN1HIF1A | |
| SCHEMBL2578845 | 0.71 | EGLN1 (0.51) | EGLN1HIF1AMEN1NPC1RAB9A | |
| SCHEMBL336458 | 0.71 | EGLN1 (0.48) | EGLN1HIF1ACALCAMEN1NPC1 | |
| SCHEMBL12101621 | 0.70 | HIF1A (0.39) | EGLN1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097620-B2 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2155746-A2 | DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | Amgen, Inc (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090099171-A1 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008137084-A2 | DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099171-A1 | Diazaquinolones that inhibit prolyl hydroxylase activity | EGLN3, EGLN2, HIF1AN | EGLN1 4/4885HIF1A 6/4885CALCA 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.